What is the role of chimeric antigen receptor (CAR) T-cell therapy in the treatment of relapsed acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Chimeric antigen receptor (CAR) T-cell therapy is being studied for use in AML that relapses after allogeneic HCT.  More than 20 clinical trials of CAR T-cell therapy in patients with AML are currently in progress. In most of those trials, the target antigens are CLL-1, CD33, or CD123. [103]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!